Inhibikase Therapeutics Net Tangible Assets

As of the most recent data (June 2026), IKT shows a net tangible assets of $150M. That compares with $80M in the prior-year period — up 91.5% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, IKT's net tangible assets is now $150M (was $80M) — a 91.5% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Inhibikase Therapeutics is outperforming or lagging.

Tracking IKT's net tangible assets over time shows whether Inhibikase Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $150M That compares with $80M in the prior-year period — up 91.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this net tangible assets page, Stockcircle has Inhibikase Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect net tangible assets (currently $150M) with ownership activity and broader fundamentals.

Inhibikase Therapeutics's net tangible assets is $150M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.